UTRxMYCN M1-14 / UTR Therap - LARVOL DELTA

In preclinical studies, UTRxMYCN M1-14, invented by Dr. Awah at UTR Therapeutics Inc., reliably targeted and degraded the oncogenic MYCN in aggressive MYCN-driven rhabdomyosarcoma, including the deadly fusion-positive rhabdomyosarcoma. (PRNewswire) - "The drug achieved on-target specificity and therapeutic efficacy, demonstrating dose-dependent inhibition of MYCN, tumor inhibition, and inhibition of liver and lung metastasis while remaining safe."

Preclinical • Rhabdomyosarcoma • Soft Tissue Sarcoma

UTR Therapeutics Inc…announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 3′UTRMYCN M1-14 (UTRxMYCN M1-14) for the treatment of soft tissue sarcoma, including rhabdomyosarcoma (RMS), and Rare Pediatric Disease Designation (RPDD) for the treatment of rhabdomyosarcoma. (PRNewswire)

FDA event • Orphan drug • Rhabdomyosarcoma • Soft Tissue Sarcoma